Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727200 | 0.88 | ALDH1A1 (0.45) | ALDH1A1TAS1R3TAS1R1TAS1R2HPGD | |
| SCHEMBL1727199 | 0.88 | ALDH1A1 (0.45) | ALDH1A1TAS1R3TAS1R1TAS1R2HPGD | |
| SCHEMBL9944747 | 0.86 | ALDH1A1 (0.53) | ALDH1A1RAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL9945003 | 0.86 | ALDH1A1 (0.53) | ALDH1A1RAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL11992707 | 0.85 | ALDH1A1 (0.48) | ALDH1A1RAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL9944827 | 0.84 | KDM1A (0.40) | ALDH1A1HPGDHCAR3CDC25B | |
| SCHEMBL9944905 | 0.82 | ALDH1A1 (0.44) | ALDH1A1RAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL9944735 | 0.82 | ALDH1A1 (0.42) | ALDH1A1RAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL9944825 | 0.82 | POLB (0.44) | ALDH1A1RAB9ANPC1POLB | |
| SCHEMBL9944914 | 0.82 | ALDH1A1 (0.42) | ALDH1A1RAB9ANPC1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759537-B2 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120214786-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | ALDH1A1 126/4885RAB9A 1033/4885NPC1 1695/4885 |
| US-20120214786-A1 | NEW COMPOUNDS | PTGER1, PTGS1, PTGES | ALDH1A1 184/4885RAB9A 2718/4885NPC1 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.